0.00Open0.00Pre Close0 Volume0 Open Interest4.50Strike Price0.00Turnover982.60%IV-45.63%PremiumDec 20, 2024Expiry Date1.41Intrinsic Value100Multiplier7DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.3316Delta0.0836Gamma1.13Leverage Ratio-0.1105Theta-0.0007Rho-0.38Eff Leverage0.0016Vega
Revance Therapeutics Stock Discussion
Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement
Crown Laboratories and Revance Therapeutics (NASDAQ: RVNC) have announced an amended merger agreement where Crown will acquire all outstanding Revance shares for $3.10 per share in cash through a tender offer. The amendment comes after several developments, including Revance's settlement with Teoxane regarding distribution agreements and revised brand guidelines, which are expect...
📊⚡️📊
No comment yet